Home » Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Jennerex presented Phase II clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
07May
-
14May
-
30May